Capturing the Value of Vaccination within Health Technology Assessment and Health Economics—Practical Considerations for Expanding Valuation by Including Key Concepts
Authors:
- Eliana BiundoEBEliana Biundo
- Mariia DronovaMDMariia Dronova
- Annie ChicoyeACAnnie Chicoye
- Richard CooksonRCRichard Cookson
- Nancy DevlinNDNancy Devlin
- T. Mark DohertyTDT. Mark Doherty
- Stephanie GarciaSGStephanie Garcia
- Antonio J. Garcia-RuizAGAntonio J. Garcia-Ruiz
- Louis P. GarrisonLGLouis P. Garrison
- Terry NolanTNTerry Nolan
- Maarten PostmaMPMaarten Postma
- David SalisburyDSDavid Salisbury
Open Access
Abstract
Following the development of a value of vaccination (VoV) framework for health technology assessment/cost-effectiveness analysis (HTA/CEA), and identification of three vaccination benefits for near-term inclusion in HTA/CEA, this final paper provides decision makers with methods and examples to consider benefits of health systems strengthening (HSS), equity, and macroeconomic gains. Expert working groups, targeted literature reviews, and case studies were used. Opportunity cost methods were applied for HSS benefits of rotavirus vaccination. Vaccination, with HSS benefits included, reduced the incremental cost-effectiveness ratio (ICER) by 1.4–50.5% (to GBP 11,552–GBP 23,016) depending on alternative conditions considered. Distributional CEA was applied for health equity benefits of meningococcal vaccination. Nearly 80% of prevented cases were among the three most deprived groups. Vaccination, with equity benefits included, reduced the ICER by 22–56% (to GBP 7014–GBP 12,460), depending on equity parameters. Macroeconomic models may inform HTA deliberative processes (e.g., disease impact on the labour force and the wider economy), or macroeconomic outcomes may be assessed for individuals in CEAs (e.g., impact on non-health consumption, leisure time, and income). These case studies show how to assess broader vaccination benefits in current HTA/CEA, providing decision makers with more accurate and complete VoV assessments. More work is needed to refine inputs and methods, especially for macroeconomic gains.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA (HO_VEO-000023)
This publication has 60 references indexed in Scilit:
- Considering equity in priority setting using transmission models: Recommendations and data needsEpidemics, 2022
- Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian CountriesApplied Health Economics and Health Policy, 2021
- How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the BatonPharmacoEconomics - Open, 2020
- Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary DiseasePharmacoEconomics - Open, 2020
- Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed ExpansionApplied Health Economics and Health Policy, 2017
- Estimating the opportunity costs of bed‐daysHealth Economics, 2017
- Eliciting the Level of Health Inequality Aversion in EnglandHealth Economics, 2016
- Respiratory viral infections during the 2009–2010 winter season in Central England, UK: incidence and patterns of multiple virus co-infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The NetherlandsThe European Journal of Health Economics, 2009
- Health-related quality of life of day-case surgery patients: a pre/posttest survey using the EuroQoL-5DQuality of Life Research, 2007